Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Given Consensus Recommendation of “Buy” by Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been assigned an average recommendation of “Buy” from the eight brokerages that are covering the stock, Marketbeat reports. Eight analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $6.63.

Several analysts recently issued reports on TSHA shares. JMP Securities reiterated a “market outperform” rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a report on Monday, January 6th. Canaccord Genuity Group lifted their price target on Taysha Gene Therapies from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Chardan Capital reiterated a “buy” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, November 14th.

Taysha Gene Therapies Trading Down 0.7 %

Shares of Taysha Gene Therapies stock opened at $1.52 on Monday. The company has a quick ratio of 5.51, a current ratio of 5.51 and a debt-to-equity ratio of 0.48. Taysha Gene Therapies has a 12-month low of $1.19 and a 12-month high of $4.32. The company has a market capitalization of $311.51 million, a price-to-earnings ratio of 2.41 and a beta of 0.95. The firm’s 50-day moving average price is $2.08 and its two-hundred day moving average price is $2.08.

Institutional Trading of Taysha Gene Therapies

A number of hedge funds have recently made changes to their positions in TSHA. Bank of New York Mellon Corp bought a new position in Taysha Gene Therapies in the 2nd quarter valued at approximately $1,018,000. Rhumbline Advisers bought a new position in shares of Taysha Gene Therapies during the second quarter valued at $413,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Taysha Gene Therapies by 109.0% during the second quarter. The Manufacturers Life Insurance Company now owns 133,213 shares of the company’s stock worth $298,000 after purchasing an additional 69,487 shares during the period. Scientech Research LLC bought a new stake in shares of Taysha Gene Therapies in the second quarter worth $97,000. Finally, SG Americas Securities LLC acquired a new stake in Taysha Gene Therapies in the third quarter valued at $129,000. 77.70% of the stock is owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.